GSK (LON:GSK) Stock Price Passes Above 200 Day Moving Average - Time to Sell?

Shares of GSK plc (LON:GSK - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,407.39 ($19.11) and traded as high as GBX 1,528.50 ($20.75). GSK shares last traded at GBX 1,527.73 ($20.74), with a volume of 15,815,270 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GSK shares. Shore Capital reiterated a "buy" rating on shares of GSK in a research report on Wednesday, April 30th. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research report on Friday, March 28th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, GSK currently has an average rating of "Moderate Buy" and a consensus price target of GBX 1,862.50 ($25.29).

GSK Price Performance

The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The stock's 50 day simple moving average is GBX 1,411.53 and its two-hundred day simple moving average is GBX 1,409.50. The stock has a market cap of £61.33 billion, a price-to-earnings ratio of 24.42, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other news, insider Emma Walmsley sold 5,473 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.67), for a total transaction of £79,303.77 ($107,676.54). Also, insider Wendy Becker acquired 536 shares of the stock in a transaction dated Thursday, March 20th. The shares were bought at an average price of GBX 1,515 ($20.57) per share, with a total value of £8,120.40 ($11,025.66). Company insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.